Antidyslipidemic action of fenofibrate in dyslipidemic-diabetic hamster model

Biochemical and Biophysical Research Communications

Volumn 305, Issue 2, 2003, Pages 215-222

  Rizvi, F ^a   Puri, A ^a   Bhatia, G ^a   Khanna, A K ^a   Wulff, E M ^b   Rastogi, A K ^a   Chander, R ^a  

^a CENTRAL DRUG RESEARCH INSTITUTE   (India)

^b NOVO NORDISK A S   (Denmark)

Author keywords

Dyslipidemia; Fenofibrate; Hamster model; Hypertriglyceridemia; Insulin impairment; Insulin resistance; Lipid lowering; Lipolysis; Lipotoxicity; PPAR

Indexed keywords

CHOLIC ACID; DEOXYCHOLIC ACID; FENOFIBRATE; HIGH DENSITY LIPOPROTEIN; LEPTIN; LIPOPROTEIN LIPASE; LOW DENSITY LIPOPROTEIN; TRIACYLGLYCEROL LIPASE; VERY LOW DENSITY LIPOPROTEIN;

ADIPOSE TISSUE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DISEASE MODEL; DOWN REGULATION; DRUG ACTIVITY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME SYNTHESIS; FATTY ACID BLOOD LEVEL; FECES; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; GLYCEROL BLOOD LEVEL; INSULIN RELEASE; LIPID DIET; LIPOLYSIS; LIPOPROTEIN BLOOD LEVEL; MALE; NONHUMAN; PHOSPHOLIPID BLOOD LEVEL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SMALL INTESTINE; TRIACYLGLYCEROL BLOOD LEVEL; UPREGULATION; WEIGHT REDUCTION;

CRICETINAE;

EID: 0038029615     PISSN: 0006291X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-291X(03)00721-6     Document Type: Article

References (43)

1. Wang P.R., Qiu G., Ippolito M., Wu M., Milot D., Ventre J., Doebber T., Wright S.D., Chao Y.S. High fat fed hamster, a unique animal model for treatment of diabetic dyslipidemia with peroxisome proliferator activated receptor α selective agonists. Eur. J. Clin. Pharmacol. 427:2001;285-293.
2. F. Rizvi, A. Puri, A.K. Khanna, G. Bhatia, R. Chander, A.K. Rastogi, Fenofibrate accelerates the catabolism of lipids in dyslipemic hamsters, in: 70th Annual Meeting of Proc. Soc. Biol. Chemists, December 2001, Hyderabad, India, pp. 189-190.
3. G. Bhatia, F. Rizvi, R. Chander, A. Puri, A.K. Khanna, E.M. Wulff, A.K. Rastogi, In vivo model for dyslipidemia in hamster (in press).
4. Staels B., Dallongeville J., Auverx J., Shoonjans K., Leitersdorf E., Fruchart J.C. Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation. 98:1998;2088-2093.
5. Elkeles R.S., Diamond J.R., Poulter C., Dhanjel S., Nicolaides A.N., Mehmood S. The SENDCAP study group. Cardivascular outcome in type 2 diabetes. A double-blind placebo controlled study of bezafibrate: the St. Mary's Ealing, Northwick Park Disease Cardiovascular Prevention (SENDCAP) Study. Diabetes Care. 21:1998;641-648.
6. Shoonjans K., Staels B., Auwerx J. Role of peroxisome proliferator activated receptors (PPAR) in mediating effects of fibrates and fatty acids on gene expression. J. Lipid Res. 37:1996;907-925.
7. Vohl M.C., Lepage P., Gaudet D., Brewer C.G., Betard C., Perron P., Houde G., Cellier C., Faith J.M., Despres J.P., Morgan K., Hudson T. Molecular scanning of the human PPARα gene: association of the L162V mutation with hyperbetalipoproteinemia. J. Lipid Res. 41:2000;945-952.
8. Shoonjans K., Watanabe M., Suzuki H., Mahfoudi A., Krey G., Wahli W., Grimaldi P., Staels B., Yamato T., Auwerx J. Induction of the acyl-coenzyme A synthase gene by fibrates and fatty acids is mediated by peroxisome proliferator response element in the C promoter. J. Biol. Chem. 270:1995;19269-19276.
9. Sniderman A., Brown B.G., Stewart B.F., Cianflone K. From familial combined hyperlipemia to hyper apo B: unravellin the overproduction of hepatic apolipoprotein. B. Curr. Opin. Lipidol. 3:1992;137-142.
10. Havel R.J., Eder H.A., Bradgo J.A. The distribution and chemical composition of ultra centrifugically separated lipoproteins in human serum. J. Clin. Invest. 34:1955;1345-1353.
11. Chard T. Laboratory Techniques in Biochemistry and Molecular Biology V-VI, part-2. fourth ed. 1990;Elsevier, Amsterdam.
12. Wing D.R., Robinson D.F. Clearing factor lipase in adipose tissue. Biochem. J. 109:1968;841-849.
13. Mays P.A., Felts J.M. The functional status of lipoprotein lipase in rat liver. Biochem. J. 108:1968;483-487.
14. Dole V.P. The microdetermination of free fatty acids. J. Lipid Res. 6:1955;151-157.
15. Lowry O.H., Rosebrough N.J., Farr A.L., Randall R. Protein measurement with Folinphenol reagent. J. Biol. Chem. 193:1951;265-275.
16. Nityanand S., Kapoor N.K. Cholesterol lowering activity of various fractions of the guggul. Ind. J. Exp. Biol. 11:1973;395.
17. Mosback E.H., Klenisky H.J., Hall P., Kendall E.E. Determination of deoxycholic and cholic acid in bile. Arch. Biochem. Biophys. 51:1954;402-409.
18. F. BoGuang, Effect of total parenteral nutrition on the exocrine and endocrine pancreas. An experimental study, Dissertation, Lund University, 1997, pp. 10-16, abstract.
19. Unger R.H. Lipotoxicity in the pathogenesis of obesity-dependent NIDDM. Diabetes. 44:1995;863-870.
20. Nakamura T., Funohashi T., Yamashita S., Nishida M., Nishida Y., Takahashi M., Hotta K., Kihara S., Nishimura T., Kishino B., Ishikawa K., Kawamoto T., Tokunaga K., Nagakawa C., Mineo I., Watanabe F., Tarui S., Matsuzawa Y. Thiozolidinedione derivatives improves fat distribution and multiple risk factors in subjects with visceral fat accumulation-double-blind placebo controlled trial. Diabetes Res. Clin. Pract. 54(3):2001;181-190.
21. The Merck Manuals of Diagnosis and Therapy, Endocrine and Metabolic Disorders (hyperlipidemia) Section-2, 15 (1995-2001) Merck & Co. NJ, USA, www.merck.com.
22. Moller D.E. New drug targets for type 2 diabetes and the metabolic syndrome. Nature. 414:2001;821-827.
23. Chang S.C., Baumann C.A., Kanzaki M., Thurmond D.C., Watson R.T., Neudauer C.L., Macara I.G., Pessin J.E., Saltiel A.R. Insulin-stimulated GLUT4 translocation requires the CAP-dependent activation of TC10. Nature. 410:2001;944-948.
24. Rolland F., Winderickx J., Thevelin J.M. Glucose-sensing mechanism in eukaryotic cells. TIBS. 26(5):2001;310-318.
25. Ruderman N.B., Saha A.K., Vavvas D., Witters L.A. Malonyl-CoA, fuel sensing, and insulin resistance. Am. J. Physiol. 276:1999;E1-E18.
26. Steppan C.M., Bailey S.T., Bhat S., Brown E.J., Banerjee R.R., Wright C.M., Patel H.P., Ahima R.S., Lazar M.A. The hormone resistin links obesity to diabetes. Nature. 409:2001;307-312.
27. Vanheek M. Diet induced obese mice develops peripheral, but not central, resistance to leptin. J. Clin. Invest. 99:1997;385-390.
28. Lee Y., Wang M.Y., Kakuma T., Wang Z.W., Babcock E., Mccorkle K., Zhou Y.T., Unger R.H. Liporegulation in diet induced obesity - the antisteatotic role of hyperlptinemia. J. Biol. Chem. 276(8):2001;5629-5635.
29. Krssak M., Falk K.P., Dresner A., Pietro L.D., Vogel S.M., Rothman D.L., Roden M., Shulman G.I. Intramyocellular lipid concentrations are correlated with insulin sensitivity in humans: a 1H NMR spectroscopy study. Diabetologia. 42:1999;113-116.
30. Ye J.M., Doyle P.J., Iglesias M.A., Watson D.G., Cooney C.J., Kraegen E.W. Peroxisome proliferated activated receptor (PPAR)-α activation lowers muscle lipids and improves insulin sensitivity in high fat fed rats. Diabetes. 50(2):2001;411-417.
31. Boden G., Chen X., Ruiz J., White J.V., Rosetti L. Mechanisms of fatty acid-induced inhibition of glucose uptake. J. Clin. Invest. 93:1994;2438-2446.
32. Chalkley S., Hettiarachi M., Chisholm D.J., Kraegen E.W. Five hour fatty acid elevation increases muscle lipids and impairs glycogen synthesis in the rat. Metabolism. 47:1998;1121-1126.
33. Schoonjans K., Peinado-Onsurbe J., Lefebvre A.M., Heyman R.A., Briggs M., Deeb S., Staels B., Auwerx J. PPARα and PPARγ activators direct a distinct tissue specific transcriptional response via a PPRE in the lipoprotein lipase gene. EMBO J. 15:1996;5336-5348.
34. Staels B., Vu-Dac N., Kosykh V., Saladin R., Fruchart J.C., Dallongeville J., Auwerx J. Fibrates down-regulate the apolipoprotein C-III expression of induction of peroxisomal acyl Co-enzyme A oxidase. J. Clin. Invest. 95:1995;705-712.
35. Peters J.M., Hennuyer N., Staels B., Fruchart J.C., Fivet C., Gonzalez F.J., Auwerx J. Alterations in lipoprotein metabolism in PPARα-deficient mice. J. Biol. Chem. 272:1997;27307-27312.
36. Shooonjans K., Staels B., Auwerx J. The peroxisome proliferator activated receptors (PPARs) and their effects on lipid metabolism and adipocyes differentiation. Biochim. Biophys. Acta. 1302:1996;93-109.
37. Auboeuf D., Riusset J., fajas L., Vallier P., Ferring V., Riou J.P., Laville M., Staels B., Auwerx J., Vidal H. Tissue distribution and quantification of the expression of the peroxisom proliferator activated receptors and LXRα mRNAs in human: effect of obesity and NIDDM in adipose tissue. Diabetes. 46:1997;1319-1327.
38. Martin G., Schoonjans K., Lefebvre A., Staels B., Auwerx J. Coordinate regulation of the expression of fatty acid transporter protein (FATP) and acyl CoA synthase (ACS) genes by PPARα and PPARγ activators. J. Biol. Chem. 272:1997;28210-28217.
39. Shoonjans K., Watanabe M., Suzuki H., Mahfoudi A., Krey G., Wahli W., Grimaldi P., Yamato T., Auwerx J. Induction of acyl CoA synthase gene by fibrates and fatty acid is by a peroxisome proliferator response element in the C promoter. J. Biol. Chem. 270:1995;19269-19276.
40. Murase T., Kondo H., Hase T., Tokimitsu I., Saito M. Abundant expression of uncoupling protein-2 in the small intestine: up-regulation by dietary fish oil and Fibrates. Biochim. Biophys. Acta. 1530:2001;15-22.
41. Tsuboyama-Kasaoka N., Takahashi M., Kim H., Ekazi O. Up-regulation of liver uncoupling protein-2 mRNA by either fish oil feeding or fibrate administration in mice. Biochem. Biophys. Res. Commun. 257:1999;879-885.
42. Patel D.D., Knight B.l., Soutar A.K., Gibbons G.F., Wade D.P. The effect of peroxisome proliferator activated receptor-α on the activity of cholesterol 7α hydroxylase gene. Biochem. J. 351(3):2000;747-753.
43. Hayhurst G.P., Lee Y.H., Lambert G., Ward J.M., Gonzalez F.J. Hepatocyte nuclear factor 4α (nuclear factor2A1) is essential for maintenance of hepatic gene expression and lipid homeostrasis. Mol. Cell. Biol. 21(4):2001;1393-1400.